Literature DB >> 7612698

Immunization by direct DNA inoculation induces rejection of tumor cell challenge.

B Wang1, M Merva, K Dang, K E Ugen, W V Williams, D B Weiner.   

Abstract

Direct DNA inoculation is the basis for a new technology that has been successfully used for in vivo induction of both humoral and cellular immune responses. However, the immunological parameters of this new approach remain to be evaluated in detail. We report here that direct DNA inoculation can induce protection from malignant tumor cell challenge through the generation of specific immune responses directed against antigens displayed on the tumor cells. The protected mice remain tumor-free for more than 1 year post-challenge. Memory responses upon tumor rechallenge were observed for both humoral and cellular immunity. Inoculated animals were able to reject otherwise lethal tumors several months following the original DNA inoculation protocol. These in vivo protective responses suggest that further analysis of this technology for vaccine development or immune therapeutic strategies is warranted.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7612698     DOI: 10.1089/hum.1995.6.4-407

Source DB:  PubMed          Journal:  Hum Gene Ther        ISSN: 1043-0342            Impact factor:   5.695


  10 in total

1.  Cellular but not humoral immune responses generated by vaccination with dendritic cells protect mice against leukaemia.

Authors:  B M Colombo; R Lacave; C Pioche-Durieu; C Masurier; F M Lemoine; M Guigon; D Klatzmann
Journal:  Immunology       Date:  2000-01       Impact factor: 7.397

Review 2.  The next wave of recombinant and synthetic anticancer vaccines.

Authors:  K R Irvine; N P Restifo
Journal:  Semin Cancer Biol       Date:  1995-12       Impact factor: 15.707

Review 3.  New therapeutic approaches based on gene transfer techniques.

Authors:  H Chong; R G Vile
Journal:  Springer Semin Immunopathol       Date:  1996

Review 4.  Immunotherapy III: Combinatorial molecular immunotherapy--a synthesis and suggestions.

Authors:  R G Vile; H Chong
Journal:  Cancer Metastasis Rev       Date:  1996-09       Impact factor: 9.264

5.  Induction of antigen-specific tumor immunity by genetic and cellular vaccines against MAGE: enhanced tumor protection by coexpression of granulocyte-macrophage colony-stimulating factor and B7-1.

Authors:  H Büeler; R C Mulligan
Journal:  Mol Med       Date:  1996-09       Impact factor: 6.354

Review 6.  Prospects for the therapeutic use of anticancer vaccines.

Authors:  R S Chamberlain
Journal:  Drugs       Date:  1999-03       Impact factor: 9.546

7.  Immunophenotypical and functional heterogeneity of dendritic cells generated from murine bone marrow cultured with different cytokine combinations: implications for anti-tumoral cell therapy.

Authors:  C Masurier; C Pioche-Durieu; B M Colombo; R Lacave; F M Lemoine; D Klatzmann; M Guigon
Journal:  Immunology       Date:  1999-04       Impact factor: 7.397

8.  Immunotherapeutic strategies targeting rheumatoid synovial T-cell receptors by DNA inoculation.

Authors:  W V Williams; Q Fang; J M Von Feldt; J D Boyer; M Luchi; B Wang; D B Weiner
Journal:  Immunol Res       Date:  1994       Impact factor: 2.829

9.  Inability to immunize patients with metastatic melanoma using plasmid DNA encoding the gp100 melanoma-melanocyte antigen.

Authors:  Steven A Rosenberg; James C Yang; Richard M Sherry; Patrick Hwu; Suzanne L Topalian; Douglas J Schwartzentruber; Nicholas P Restifo; Leah R Haworth; Claudia A Seipp; Linda J Freezer; Kathleen E Morton; Sharon A Mavroukakis; Donald E White
Journal:  Hum Gene Ther       Date:  2003-05-20       Impact factor: 5.695

10.  Adjuvant effects of L. acidophilus LW1 on immune responses to the foot-and-mouth disease virus DNA vaccine in mice.

Authors:  Junhong Su; Jidong Li; Haixue Zheng; Yanan You; Xuenong Luo; Yungang Li; Xueqiang Li; Xusheng Ma; Junjun Li; Yongxi Dou; Xuepeng Cai
Journal:  PLoS One       Date:  2014-08-13       Impact factor: 3.240

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.